肌萎缩
内分泌学
内科学
激素
骨骼肌
脂肪组织
肌肉萎缩
内分泌系统
肌生成抑制素
医学
生物
作者
Teresa Priego,Ana Isabel Morales Martín,Daniel González-Hedström,Miriam Granado,Asunción López‐Calderón
出处
期刊:Vitamins and hormones
日期:2021-01-01
卷期号:: 535-570
被引量:35
标识
DOI:10.1016/bs.vh.2020.12.021
摘要
Aging involves numerous changes in body composition that include a decrease in skeletal muscle mass. The gradual reduction in muscle mass is associated with a simultaneous decrease in muscle strength, which leads to reduced mobility, fragility and loss of independence. This process called sarcopenia is secondary to several factors such as sedentary lifestyle, inadequate nutrition, chronic inflammatory state and neurological alterations. However, the endocrine changes associated with aging seem to be of special importance in the development of sarcopenia. On one hand, advancing age is associated with a decreased secretion of the main hormones that stimulate skeletal muscle mass and function (growth hormone, insulin-like growth factor 1 (IGFI), testosterone and estradiol). On the other hand, the alteration of the IGF-I signaling along with decreased insulin sensitivity also have an important impact on myogenesis. Other hormones that decline with aging such as the adrenal-derived dehydroepiandrosterone, thyroid hormones and vitamin D seem to also be involved in sarcopenia. Adipokines released by adipose tissue show important changes during aging and can affect muscle physiology and metabolism. In addition, catabolic hormones such as cortisol and angiotensin II can accelerate aged-induced muscle atrophy, as they are involved in muscle wasting and their levels increase with age. The role played by all of these hormones and the possible use of some of them as therapeutic tools for treating sarcopenia will be discussed.
科研通智能强力驱动
Strongly Powered by AbleSci AI